Skip to main content
. 2022 Dec 19;29(5):899–909. doi: 10.1158/1078-0432.CCR-22-2538

Figure 5.

Figure 5. Overall survival based on molecular response assessment and radiological response evaluation after treatment. Overall survival was compared for the 46 patients with cfDNA assessment prior to treatment. A, Overall survival and molecular response evaluation to treatment based on ctDNA (HR = 2.4; log-rank P = 0.039). The molecular response was defined as ctDNA clearance over 98% after treatment compared with the initial baseline ctDNA measurement. B, Overall survival and radiological response evaluation of CT images (HR = 1.8; log-rank P = 0.197). The radiological response was based on the RECIST evaluation after treatment. cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; CT, computed tomography; HR, hazard ratio; WBC, white blood cell.

Overall survival based on molecular response assessment and radiological response evaluation after treatment. Overall survival was compared for the 46 patients with cfDNA assessment prior to treatment. A, Overall survival and molecular response evaluation to treatment based on ctDNA (HR = 2.4; log-rank P = 0.039). The molecular response was defined as ctDNA clearance over 98% after treatment compared with the initial baseline ctDNA measurement. B, Overall survival and radiological response evaluation of CT images (HR = 1.8; log-rank P = 0.197). The radiological response was based on the RECIST evaluation after treatment. cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; CT, computed tomography; HR, hazard ratio; WBC, white blood cell.